BioPharma Dive January 30, 2025
Takeda’s U.S. head Julie Kim will replace Weber in June 2026, becoming one of the few female CEOs of a top drugmaker.
Takeda CEO Christophe Weber plans to retire next year after a decade steering the Japanese drugmaker, a tenure in which he led Takeda through one of the largest pharmaceutical mergers in history and a major research and development revamp.
Julie Kim, currently president of the company’s U.S. business unit, will succeed Weber, backed by a unanimous vote of Takeda’s board. Kim, a graduate of Dartmouth University and Northwestern’s Kellogg School of Management, spent more than 13 years at Baxter International and then worked for the Baxter spinoff Baxalta, which became part of Shire in 2016 and then Takeda...
Today's Sponsors
Today's Sponsor